DYAI — DYADIC INTERNATIONAL INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1213809 ·
Last close
$1.05
Market Cap
$38.26M
52W High
$1.60
52W Low
$0.66
ADV30
251,218
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 623,590 | -168,250 | -1,912,284 | -1,954,683 | 7,809,573 | 4,247,269 | 8,217,305 |
| Dec 2025 | 235,716 | -148,892 | -1,524,929 | -1,567,263 | 9,945,725 | 4,622,331 | 8,713,315 |
| Sep 2025 | 350,046 | -673,957 | -1,912,614 | -1,976,012 | 11,672,757 | 5,834,510 | 9,065,423 |
| Jun 2025 | 463,449 | -150,142 | -1,712,970 | -1,793,774 | 8,138,046 | 2,140,899 | 8,667,747 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,715,824
Investing CF
$866,177
Financing CF
$4,940,695
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-95,405,791
Inventory
—
Receivables
$1,008,887
ST Investments
$1,361,043
EBIT TTM
$-6,840,216
Pretax Income TTM
$-7,291,732
Interest Exp TTM
$451,516
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,807,729
EBITDA
—
Free Cash Flow
$-4,185,846
Enterprise Value
$38,434,524
Total Cash
$5,608,312
Total Debt
$5,053,423
Shares Out
36,438,703
Trailing EPS
$-0.21
Book Value
$-0.01
ROE
-2826.9%
ROA
-56.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,232,311 | -7,145,916 | -7,364,628 | 9,945,725 | 8,713,315 | — | -5,702,221 |
| Dec 2024 | 3,495,389 | -5,878,261 | -5,809,159 | 9,930,275 | 7,459,985 | — | -3,974,806 |
| Dec 2023 | 2,898,806 | -8,191,322 | -6,795,461 | 8,219,236 | 2,340,651 | — | -6,726,755 |
| Dec 2022 | 2,930,303 | -10,115,760 | -9,735,258 | 13,712,818 | 2,625,079 | — | -8,083,775 |
TTM Snapshot
Revenues TTM
$717,467
NetIncome TTM
$-3,237,879
OpCashFlow TTM
$0
Assets (Latest)
$37,452,496
Forward EPS
$-0.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELUT | ELUTIA INC. | $37.88M | $0.86 | — |
| EXOZ | EXOZYMES INC. | $43.16M | $4.65 | — |
| MGX | Metagenomi Therapeutics, Inc. | $44.80M | $1.19 | — |
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
News headlines (Yahoo Finance, 1h cache)
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
2026-07-28 12:30 · Yahoo
Dyadic Announces Continued Listing on the Nasdaq Capital Market
2026-07-24 11:30 · Yahoo
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
2026-07-16 12:00 · Yahoo
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
2026-07-07 11:25 · Yahoo
Dyadic Expands IP Protection and Business Development Activities in Japan
2026-06-29 11:25 · Yahoo
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
2026-06-22 12:46 · Yahoo
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
2026-06-15 11:25 · Yahoo
Dyadic (DYAI) Q1 2026 Earnings Call Transcript
2026-06-02 16:39 · Yahoo
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
2026-05-28 11:25 · Yahoo
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-21 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.